

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/>

**How to cite:**

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

© 2023, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>.



**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk).

## Journal Pre-proofs


Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England

Carly Meyer, Louis Goffe, Vivi Antonopoulou, Fiona Graham, Mei Yee Tang, Jan Lecouturier, Aikaterini Grimani, Paul Chadwick, Falko F Sniehotta

PII: S0264-410X(23)00182-2  
DOI: <https://doi.org/10.1016/j.vaccine.2023.02.047>  
Reference: JVAC 24763

To appear in: *Vaccine*

Received Date: 7 February 2022  
Revised Date: 21 December 2022  
Accepted Date: 13 February 2023



Please cite this article as: C. Meyer, L. Goffe, V. Antonopoulou, F. Graham, M. Yee Tang, J. Lecouturier, A. Grimani, P. Chadwick, F.F. Sniehotta, Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England, *Vaccine* (2023), doi: <https://doi.org/10.1016/j.vaccine.2023.02.047>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Ltd.

**Title: Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England**

Short title: *Understanding decision-making about COVID-19 booster vaccination*

Carly Meyer<sup>1\*</sup>, Louis Goffe<sup>2</sup>, Vivi Antonopoulou<sup>1</sup>, Fiona Graham<sup>2</sup>, Mei Yee Tang<sup>2</sup>, Jan Lecouturier<sup>2</sup>, Aikaterini Grimani<sup>3</sup>, Paul Chadwick<sup>1</sup>, Falko F Sniehotta<sup>2,4</sup>

<sup>1</sup> NIHR Policy Research Unit in Behavioural Science – Health Psychology Research Group, Department of Clinical, Education and Health Psychology, University College London, UK

<sup>2</sup> NIHR Policy Research Unit in Behavioural Science – Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, UK

<sup>3</sup> NIHR Policy Research Unit in Behavioural Science – Behavioural Science Group, Warwick Business School, University of Warwick, UK

<sup>4</sup> Department of Public Health, Preventive and Social Medicine, Center for Preventive Medicine and Digital Health Baden-Wuerttemberg, Heidelberg University, Germany

\*Corresponding author information: Carly Meyer, Department of Clinical, Educational and Health Psychology, Centre for Behaviour Change, University College London, 1-19 Torrington Place, London WC1E 7HB, United Kingdom (e-mail: [carly.meyer@ucl.ac.uk](mailto:carly.meyer@ucl.ac.uk)).

**Abstract**

*Background:* COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19.

*Purpose:* To use the Precaution Adoption Process Model (PAPM) to understand decision-making about the COVID-19 booster vaccine (CBV) in England.

*Methods:* An online, cross-sectional survey informed by the PAPM, the extended Theory of Planned Behaviour and Health Belief Model administered to people over the age of 50 residing in England, UK in October 2021. A multivariate, multinomial logistic regression model was used to examine associations with the different stages of CBV decision-making.

*Results:* Of the total 2,004 participants: 135 (6.7%) were unengaged with the CBV programme; 262 (13.1%) were undecided as to whether to have a CBV; 31 (1.5%) had decided not to have a CBV; 1,415 (70.6%) had decided to have a CBV; and 161 (8.0%) had already had their CBV. Being unengaged was *positively* associated with beliefs in their immune system to protect against COVID-19, being employed, and low household income; and *negatively* associated with CBV knowledge, a positive COVID-19 vaccine experience, subjective norms, anticipated regret of not having a CBV, and higher academic qualifications. Being undecided was *positively* associated with beliefs in their immune system and having previously received the Oxford/AstraZeneca (as opposed to Pfizer/BioNTech) vaccine; and *negatively* associated with CBV knowledge, positive

attitudes regarding CBV, a positive COVID-19 vaccine experience, anticipated regret of not having a CBV, white British ethnicity, and living in East Midlands (vs. London).

*Conclusions:* Public health interventions promoting CBV may improve uptake through tailored messaging directed towards the specific decision stage relating to having a COVID-19 booster.

**Keywords:**

Coronavirus, vaccine hesitancy, booster vaccination, Precaution Adoption Process Model, health belief model, theory of planned behaviour

**Introduction**

With the emergence of new variants [1] and concerns over waning immunity against COVID-19 in the months following the second dose of a COVID-19 vaccine [2, 3], COVID-19 continues to pose a threat to public health in countries where vaccination coverage for COVID-19 is high. Booster vaccines have been shown to be safe and effective [4] and deemed by governments globally to be a critical component in the ongoing public health efforts to protect their populations from serious illness or death [5]. On 14 September 2021, the Joint Committee on Vaccination and Immunisation (JCVI) provided independent guidance to UK governmental health authorities on the administration of the booster vaccine [6] which has since been updated to include all people over the age of 18 who received their vaccine a minimum of three months prior [7]. In England, COVID-19 vaccination is centrally organised through the

Department of Health and Social Care in collaboration with NHS England, NHS Improvement, and the UK Health Security Agency and is available for free at the point of access. The success of the booster programme relies on people having the vaccine once offered. In the first three months of the booster programme (September 16 – December 12, 2021), 79.4% of adults in England over the age of 50 who had received two doses of the COVID-19 vaccine had received a third dose [8]. Estimations of the vaccine coverage required to achieve and sustain herd immunity vary depending on levels of natural infection, vaccine effectiveness against new variants, and waning immunity [9]; however, modelling suggests that 72% of a highly-vaccinated population (where  $\geq 59\%$  of the population are fully vaccinated) need to receive a booster vaccine to sustain population-level immunity against COVID-19, accounting for waning immunity [10].

COVID-19 booster vaccines are likely to be administered annually whilst COVID-19 continues to circulate [11]. Therefore, to optimise future booster vaccine uptake, health officials and policymakers need to understand why some people may be reluctant to receive the booster vaccine. The (extended) Theory of Planned Behaviour (TPB) [12, 13] and Health Belief Model (HBM) [14] have been used extensively to understand determinants of COVID-19 vaccine intention [15-18]. Factors found to be associated with the intention to receive a COVID-19 vaccine vary across studies, though those that have most consistently been shown to significantly influence intention include more perceived benefits [16, 18], more positive beliefs and attitudes towards COVID-19 vaccination [15, 18, 19], greater perceived knowledge about vaccination [18, 19], and stronger subjective norms [16, 18]. Other factors associated with COVID-19 vaccine intention include previous influenza vaccination [16, 18-20], trust [15, 18],

and socio-demographic characteristics including age, ethnicity, education, sex, and relative affluence [16, 19, 20]. It is not yet known if these factors will be associated with intentions to have a COVID-19 booster vaccine, particularly as to be eligible, one must have already received the primary course of an approved COVID-19 vaccine.

Importantly, the views of those individuals who are hesitant to have a COVID-19 booster vaccine are unlikely to be homogenous [21, 22]. One way to model these differences is to reference stage theory, which postulates that people within the same stage of decision making may face similar barriers to stage transition, whereas people in different stages face different barriers [23, 24]. Therefore, it is important that we understand what factors differentiate people at different stages of decision-making about the booster vaccine so that Government and public health officials can tailor their interventions accordingly to optimise uptake [25]. The Precaution Adoption Process Model (PAPM) was developed to facilitate our understanding of decision-making in the context of a novel threat to health [23, 24] and has been used to understand decision making about human papillomavirus (HPV) vaccination [26, 27]. The PAPM conceptualises seven unique stages of decision-making that one might move through, including being unaware of a precautionary action (not heard of COVID-19 booster vaccination) (Stage 1), being aware but unengaged in the decision to act or not (not thought about having the booster vaccine) (Stage 2), being undecided about whether or not to act (undecided about having the booster vaccine) (Stage 3), deciding not to act (deciding not to have booster vaccine) (Stage 4), deciding to act (deciding to have booster vaccine) (Stage 5), taking action (having a booster vaccine) (Stage 6) and maintaining action (routine vaccination) (Stage 7) [23, 24]. Unlike other stage theories, the PAPM does not specify a time period for behaviour change to occur and

acknowledges that people who have no intention to change their behaviour may have never heard of the precautionary action, not thought about taking action, or decided not to act [23].

The aim of the present study was to (1) use the PAPM to profile the general public's decision-making about having a COVID-19 booster vaccine (CBV); and (2) examine associations between PAPM stage and individuals' experiences of receiving their first and second COVID-19 vaccines, attitudes and beliefs about CBV, personal health characteristics, and socio-demographic characteristics.

## **Method**

### *Design*

An online, cross-sectional, population-based survey was administered to the general public residing in England between October 11 - 20, 2021, approximately 4 weeks after the JCVI published their initial guidance [6]. We obtained ethical approval for the study from a UK university Ethics Committee (Reference: 13754/2020) [please note that identifiable information removed for the peer review process].

### *Participants*

Individuals were eligible to participate in this study if: they resided in England, UK; were fully vaccinated against COVID-19 (i.e., received two doses of the Oxford/AstraZeneca, Pfizer/BioNTech, or Moderna vaccine (or combination of vaccines); or one dose of the Janssen vaccine); and over the age of 50. These criteria were consistent with the age-based eligibility criteria for CBV at the time we administered the survey. Quotas were used to ensure national



representativeness with respect to gender and region. All participants were recruited using Qualtrics, a market research company.

### *Materials*

The questionnaire was adapted from one we administered previously to capture psychological determinants of COVID-19 vaccine intention in people who were either undecided or had decided not to have the vaccine [18].

### *PAPM stage for COVID-19 booster vaccination*

To categorise participants by PAPM stage, participants were asked “Which of the following best describes your thoughts about having a COVID-19 booster vaccine, once Public Health authorities recommend you have one?” and were asked to select one of six options that represented Stages 2 to 6 (see Appendix A). We did not include options that related to Stage 1 (unaware) because COVID-19 booster vaccination was well publicised; or Stage 7 (maintenance) because the booster vaccine programme had only just commenced.

### *Previous vaccine experience*

Questions focused on individuals’ overall experiences of receiving their first and second vaccine (5 items), the quality of the healthcare environment (6 items) and patient-provider connection (4 items) when they received their second COVID-19 vaccine (adapted from the HEAL short form items [28]), vaccine access (3 items), and the perceived benefits from COVID-19 vaccination (3 items) (see Appendix A). All items were measured on a 5-point Likert scale, with higher scores representing more positive experiences. Items pertaining to each of the 5

subscales had good internal consistency (Cronbach's alpha 0.68-0.91) and so subscale scores are reported as a single mean score.

#### *Beliefs and attitudes about COVID-19 and COVID-19 booster vaccination*

The extended TPB [12, 13] and HBM [14] were used to understand individuals' beliefs and attitudes about COVID-19 and COVID-19 booster vaccination. Regarding the extended TPB, we captured vaccine attitudes (2 items), vaccine subjective norms (4 items), vaccine perceived control (1 item), and anticipated regret (3 items). Regarding the HBM, we captured perceived severity (1 item), perceived susceptibility (3 items), perceived benefits (6 items), and perceived vaccine safety (2 items). Other factors deemed relevant included knowledge about vaccine effectiveness, vaccine safety, and transmissibility of COVID-19 post-vaccination (3 items) [29]; trust in Government (1 item; adapted from [30]); and fear of needles (1 item; [13]). Items were based on items used in similar studies that have examined the psychological determinants of vaccine intention [13, 19, 31, 32] and are presented in Appendix A. All items (except 'fear of needles') were measured on a 5-point Likert scale, with higher scores representing higher levels of agreement / more anticipated regret. Except for 'perceived susceptibility', all constructs had good internal consistency (Cronbach's alpha 0.70-0.97) and thus each were represented as a single mean score.

#### *Personal health characteristics and socio-demographic characteristics*

Participants were asked to rate their general health, if they had been asked to shield from COVID-19, or had previously had COVID-19. Socio-demographic and socio-economic questions

asked for participants' age, gender, region, ethnicity, education status, employment status, keyworker status, and household income.

### *Patient and public involvement*

Our dedicated patient and public involvement team (N = 6, five aged 50+ years consistent with target population) reviewed the survey on two occasions to (1) ensure the survey items were relevant and easily interpretable and (2) the online survey was easy to navigate.

### *Data analysis*

All analyses were conducted using STATA (version 16). We examined univariate associations between PAPM stage, and 6 factors related to previous COVID-19 vaccine experiences, 13 psychological factors, 3 personal health characteristics, and 6 socio-demographic and 3 socio-economic factors, using a series of univariate regression models. Only significant variables ( $p < 0.10$ ) were considered for inclusion in the multivariate model. Pairwise correlations were computed between all significant ( $p < 0.10$ ) continuous variables; the variable 'healthcare environment' was dropped because it was highly correlated with 'patient-provider connection' ( $r = 0.74$ ). All other correlations were less than 0.7. Multi-collinearity was checked and all variation inflation factor (VIF) values were less than 5.0. A multivariate, multinomial logistic regression model was fitted to the data using backward stepwise selection based on p-values ( $p < 0.10$ ). Participants in PAPM Stage 5 (decided to act) were compared to participants in Stage 2 (unengaged) and Stage 3 (undecided). Participants in PAPM Stage 4 (decided not to act) were excluded because the sample size was too small; and participants in PAPM Stage 6 (vaccinated) were excluded because not all people were eligible to have the booster vaccine at

the time we conducted the study. The relative risk ratios (RRR) and 95% confidence intervals are reported; RRRs < 1 indicate a negative association with PAPM stage and RRRs > 1 indicate a positive association. Studentised residuals were calculated to identify possible outliers. No outliers were identified (all residuals <  $\pm 2.58$ ). The pseudo  $r^2$  value is reported to indicate goodness of fit.

## Results

Overall, 2,004 participants completed the survey (see Table 1 for a summary of sample characteristics). Of these, 135 (6.7%) participants indicated they were in Stage 2 (unengaged), 262 (13.1%) participants were in Stage 3 (undecided), 31 (1.5%) participants were in Stage 4 (decided not to act), 1,415 (70.6%) participants were in Stage 5 (decided to act), and 161 (8.0%) participants were in Stage 6 (had booster vaccine). Descriptive statistics are presented for each of the potential explanatory variables, pertaining to socio-demographic, socio-economic, and health information (see Table 2) and previous COVID-19 vaccine experiences and psychological constructs (see Table 3), by PAPM stage.

[insert Tables 1-3 here]

The multivariate model is presented in Table 4. Of the 30 potential explanatory variables, 28 were considered for inclusion in the multivariate model. The final model (log likelihood = -782.78, LR  $\chi^2$  (28) = 518.71, pseudo  $r^2$  = 0.249,  $p$  < 0.0001) was based on 1,637 participants and revealed 12 significant predictors of PAPM stage (adjusted  $p$  < 0.05). Factors *positively* associated with being 'unengaged' included stronger beliefs that their immune system was strong enough to protect against COVID-19, being employed, and having a household income <

£30,000; factors *negatively* associated with being ‘unengaged’ included greater booster vaccine knowledge, a better experience with their previous COVID-19 vaccine, stronger subjective norms, more anticipated regret, and having a high school qualification, University diploma or degree, or other qualification (vs. no qualification). Factors *positively* associated with being ‘undecided’ included stronger beliefs that their immune system was strong enough to protect against COVID-19 and having received the Oxford/AstraZeneca previously (vs Pfizer/BioNTech); factors negatively associated with being ‘undecided’ included greater booster vaccine knowledge, positive attitudes towards the booster vaccine, a better experience with their previous COVID-19 vaccine, more anticipated regret, white British ethnicity, and living in East Midlands (vs. London).

[insert Table 4 here]

## Discussion

Our results indicated that approximately 20% of those eligible had not yet decided to have a CBV in the early stages of the booster programme in England. A variety of factors related to individuals’ previous vaccine experiences, their attitudes and beliefs towards COVID-19 booster vaccination, and socio-demographic and socio-economic factors differentiated people who were ‘unengaged’ and ‘undecided’, from people who had made the decision to have the booster vaccine. People were considered ‘unengaged’ if they had not yet thought about having the booster vaccine; and ‘undecided’ if they had considered taking action but remained uncertain [23]. Some factors were consistent across both stages; however, differences also

emerged highlighting the utility of applying the PAPM model to understand decision-making about the COVID-19 booster vaccine.

The most important factors that differentiated people in both the 'unengaged' and 'undecided' groups from people who had decided to have the booster vaccine, included knowledge about the safety and effectiveness of the booster vaccine and the perception that the immune system was strong enough to protect against COVID-19 (perceived susceptibility). Knowledge gaps were identified as a significant predictor of COVID-19 vaccine intention earlier in the pandemic prior to the approval of a COVID-19 vaccine [18, 19] and the fact that it remains a strong predictor indicates that public education about the safety and effectiveness of the booster vaccine needs to be a priority. Public understanding of COVID-19 vaccination has likely changed over the course of the pandemic, as more becomes known about vaccine side effects [33-35] and their effectiveness against new variants of the virus [36, 37]. In contrast to knowledge, perceived susceptibility has not previously been shown to predict COVID-19 vaccine intention or behaviour, like it has for other illnesses such as HPV and seasonal flu [27, 38]. Our results indicate that perceived susceptibility might have shifted during the pandemic now that there are high levels of immunity among the community, either from vaccination or natural infection. This might have translated into beliefs that the immune system is sufficiently strong to protect against COVID-19 without need for further protection from a booster vaccine.

More negative experiences with the primary course of the COVID-19 vaccine were associated with being both 'unengaged' and 'undecided' about the booster vaccine, and is consistent with previous research showing that people who have experienced vaccine-related side-effects in the past are more hesitant to have vaccines in adulthood [39]; and conversely,

positive past experiences are associated with greater vaccine uptake [40]. This suggests that more needs to be done to understand and address concerns in those that experienced unpleasant side effects from previous doses of the COVID-19 vaccine as a specific subgroup of the population who may be vaccine hesitant.

Attitudes towards the booster vaccine was uniquely associated with being undecided about having the vaccine once available to them, as was having had the Oxford/AstraZeneca vaccine previously as opposed to the Pfizer/ BioNTech vaccine. Attitudes have consistently been identified as a strong predictor of COVID-19 vaccine intention [15, 18, 19]; however, the fact that vaccine type is associated with vaccine hesitancy is a novel finding. This latter finding might reflect some apprehension about combining vaccines, given that JCVI recommended that the Pfizer/BioNTech or Moderna vaccine be administered as the booster vaccine in England [6]. Alternatively, it might reflect the high level of media coverage of the rare but serious adverse effects from the Oxford/AstraZeneca vaccine [41]. This finding requires further investigation.

Disparities in protection from COVID-19 have widened during the UK vaccine roll out as minority ethnic groups are less likely to take up vaccination than the majority white population [42-44]. The present results indicate that this may worsen during the booster vaccine rollout given that people of minority ethnic heritage were more likely to be undecided about having a booster vaccine than those from a white British background. Indeed, recent reports indicate that booster vaccine uptake is consistently highest among people of white ethnicity and lowest amongst people who are Black or South Asian [45, 46]. It might also help explain the finding that people who live in East Midlands were less likely than people in London to be “undecided” about having the booster vaccine; there was a higher proportion of ethnic diversity among

participants living in London, with about one-quarter reporting an ethnicity other than white British, compared to 3% living in East Midlands. This finding should be interpreted with caution, however, given that sample sizes became small when the data were categorised into one of nine regions in England and no other regional comparisons with London were significant. All considered, it will be important to continue public health efforts that have been implemented successfully over the course of the pandemic to improve booster vaccine uptake among people from minority ethnic groups in order to prevent existing disparities from widening [44].

A combination of socio-economic factors also uniquely differentiated people who were 'unengaged' from people who had decided to have the vaccine, including a greater likelihood of being in the workforce and having a household income less than £30,000, as well as a lower likelihood of having a formal qualification. In addition, people who had not yet engaged in the decision-making process were exposed to weaker social pressure (subjective norms) to have the booster vaccine [16, 18]. Given that subjective norms are strongly influenced by exposure to the attitudes and behaviours of family, friends and colleagues within a community, it is important that efforts are made to engage, understand and work with the specific barriers to booster vaccination uptake in more deprived communities. For example, despite UK Government guidance recommending employers support vaccination by allowing time off to get vaccinated and to review their sick leave policies [47], some workplaces do not allow their employees to receive the booster vaccine during working hours or may not provide paid leave in the event of negative side effects [48].

#### *Policy recommendations*



Overall, our results suggest that public health interventions for COVID-19 booster vaccination need to incorporate a combination of general and more targeted approaches to achieve maximum impact. Efforts to educate the public about the safety and effectiveness of booster vaccines needs to continue, particularly as new variants emerge that pose new threats to public health, and likewise, the public need to be informed that a strong immune system is not sufficient to protect them from contracting COVID-19. To support booster vaccine uptake in people currently unengaged in the decision-making process, more research is needed to understand the additional barriers faced by people with less financial security so that the necessary support can be made available. For example, some workplaces may require on-site vaccination access or the Government may need to provide paid sick leave to those who are not well enough to work after having their booster vaccine. To help increase perceived social norms, role models could be used to deliver messages about social acceptance of booster vaccination, which has been shown to be effective at increasing vaccine intention for hepatitis B [49]. In light of our findings which indicate that people from minority ethnic backgrounds are more likely to be undecided about having a COVID-19 booster vaccine, it will be important that public health efforts aimed at supporting vaccine uptake in these populations are continued. This could involve working with local communities to build trust in health systems, providing culturally appropriate educational materials, listening to and addressing specific fears and concerns, addressing misinformation, and making booster vaccines available in religious venues and other community venues [44, 50-52].

*Methodological limitations and future directions*

The following limitations need to be taken into consideration when interpreting our findings. Firstly, data were collected at the beginning of the booster vaccine rollout and therefore it is possible that some people may not have been aware of the COVID-19 booster program at the time of the study and were incorrectly assigned to PAPM Stage 2 (instead of Stage 1). Likewise, the number of people who had already decided they would not have a booster vaccine was too small to allow for any further analyses, meaning we need to learn more about why previously vaccinated people do not want a booster vaccine. Secondly, the study was conducted prior to the emergence of the Omicron variant in November 2021 [1]. Despite our study being based on stable and well-validated theoretical constructs, it is not certain if these findings would reflect current decision-making about the COVID-19 booster vaccine. Thirdly, we only captured data for people who were eligible for the booster vaccine at the time of data collection, and therefore we do not know if the findings would generalise to people aged less than 50 years. Lastly, our sample was a predominantly white British sample and therefore more research is needed to better understand the reasons for vaccine hesitancy among people from ethnic minority groups. Future research should draw on behavioural science models and frameworks such as the Behaviour Change Wheel [53] to design and evaluate public health measures to promote vaccine uptake among those who have not yet decided to have a COVID-19 booster vaccine. More research is needed to understand individuals' past experiences with COVID-19 vaccination among people who are vaccine hesitant, to see if and how there is scope to intervene to support future vaccination. Likewise, the association between COVID-19 vaccine type and vaccine decision-making warrants further

investigation so that public health interventions can appropriately address the underlying reason/s for this association.

### *Conclusion*

Our results demonstrate the usefulness of applying the PAPM to understand decision-making about the CBV, and subsequently propose policy recommendations to increase booster vaccine uptake among people who are 'unengaged' or 'undecided'. Given that being 'unengaged' and 'undecided' was associated with less perceived knowledge about the safety and effectiveness of the booster vaccine and less perceived susceptibility, we propose that public health policy prioritise educating the public about the safety and efficacy of booster vaccination and dispel beliefs that a healthy immune system alone will protect against COVID-19. Being 'unengaged' was uniquely associated with a combination of socio-economic factors, as well as weaker subjective norms, highlighting the need to understand the additional barriers faced by people who have less financial security, and to understand the social processes facilitating CBV uptake among these people. Attitude towards the booster vaccine was uniquely associated with being undecided about having the vaccine once available to them, as was not being of white British ethnicity. Therefore, public health efforts aimed at shifting attitudes and supporting vaccine uptake in minority ethnic groups should continue. Future research should draw on behavioural science models and frameworks such as the Behaviour Change Wheel to design and evaluate public health measures to promote CBV uptake.

### **Acknowledgements**

We would like to thank the participants for taking the time to participate in this study. We would also like to thank [name omitted for peer review] and our dedicated PPI group for their input into survey design, including [names omitted for peer review].

**Funding:** This paper is independent research commissioned and funded by the National Institute for Health Research Policy Research Programme. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or its arm's length bodies, and other Government Departments. This project is funded by the National Institute for Health Research (NIHR) [Policy Research Unit in Behavioural Science (project reference PR-PRU1217-20501)].

## References

1. World Health Organization. *Update on Omicron*. 2021 28 November 2021 Available from: <https://www.who.int/news/item/28-11-2021-update-on-omicron>.
2. Goldberg, Y., et al., *Waning Immunity after the BNT162b2 Vaccine in Israel*. N. Engl. J. Med., 2021.DOI: 10.1056/NEJMoa2114228.
3. Levin, E.G., et al., *Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months*. N. Engl. J. Med., 2021.DOI: 10.1056/NEJMoa2114583.
4. Bar-On, Y.M., et al., *Protection of BNT162B2 vaccine booster against covid-19 in Israel*. N. Engl. J. Med., 2021. **385**(15): p. 1393-1400.DOI: 10.1056/NEJMoa2114255.
5. World Health Organization. *WHO SAGE roadmap for prioritizing use of COVID-19 vaccines*. January, 2022 Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2022.1>.
6. Department of Health & Social Care. *Independent report: JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022*. 2021 Available from: <https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022>.
7. Department of Health & Social Care. *JCVI advice on the UK vaccine response to the Omicron variant, 29 November 2021*. 2021 Available from: <https://www.gov.uk/government/publications/uk-vaccine-response-to-the-omicron-variant-jcvi-advice/jcvi-advice-on-the-uk-vaccine-response-to-the-omicron-variant>.
8. Office for National Statistics. *Coronavirus and vaccination rates in people aged 50 years and over by sociodemographic characteristic, England: 8 December 2020 to 12 December 2021*. 2021 Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthinequalities/bulletins/coronavirusandvaccinationratesinpeopleaged70yearsandoverbysociodemographiccharacteristicengland/8december2020to12december2021>.
9. Sanz-Leon, P., et al., *Modelling herd immunity requirements in Queensland: Impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2*. Philosophical Transactions of the Royal Society A, 2022. **380**(2233): p. 20210311.DOI: doi:10.1098/rsta.2021.0311.
10. Safdar, S., C.N. Ngonghala, and A.B. Gumel, *Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States*. Mathematical Biosciences and Engineering, 2023. **20**(1): p. 179-212.DOI: 10.3934/mbe.2023009.
11. Mabbott, N., *COVID vaccines: An annual booster like the flu shot could be the way forward, in The Conversation*. October, 2022.
12. Ajzen, I., *The theory of planned behavior*. Organ Behav Hum Decis Process, 1991. **50**(2): p. 179–211.

13. Myers, L.B. and R. Goodwin, *Determinants of adults' intention to vaccinate against pandemic swine flu*. BMC Public Health, 2011. **11**(1): p. 15.DOI: 10.1186/1471-2458-11-15.
14. Rosenstock, I.M., *The Health Belief Model and preventive health behavior*. Health Educ. Monogr., 1974. **2**(4): p. 354-386.DOI: 10.1177/109019817400200405.
15. Breslin, G., et al., *COVID-19 vaccine uptake and hesitancy survey in Northern Ireland and Republic of Ireland: Applying the theory of planned behaviour*. PLoS ONE, 2021. **16**(11): p. e0259381.DOI: 10.1371/journal.pone.0259381.
16. Shmueli, L., *Predicting intention to receive COVID-19 vaccine among the general population using the Health Belief Model and the Theory of Planned Behavior model*. BMC Public Health, 2021. **21**(1): p. 804.DOI: 10.1186/s12889-021-10816-7.
17. Wolff, K., *COVID-19 vaccination intentions: The Theory of Planned Behavior, optimistic bias, and anticipated regret*. Front. Psychol, 2021. **12**: p. 648289-648289.DOI: 10.3389/fpsyg.2021.648289.
18. Goffe, L., et al., *Factors associated with vaccine intention in adults living in England who either did not want or had not yet decided to be vaccinated against COVID-19*. Hum. Vaccines Immunother., 2021.DOI: <https://dx.doi.org/10.1080/21645515.2021.2002084>.
19. Sherman, S.M., et al., *COVID-19 vaccination intention in the UK: Results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey*. Hum. Vaccines Immunother., 2020: p. 1-10.DOI: 10.1080/21645515.2020.1846397.
20. Head, K.J., et al., *A national survey assessing SARS-CoV-2 vaccination intentions: Implications for future public health communication efforts*. Sci Commun., 2020. **42**(5): p. 698-723.DOI: 10.1177/1075547020960463.
21. Larson, H.J., et al., *Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012*. Vaccine, 2014. **32**(19): p. 2150-9.DOI: 10.1016/j.vaccine.2014.01.081.
22. MacDonald, N.E., *Vaccine hesitancy: Definition, scope and determinants*. Vaccine, 2015. **33**(34): p. 4161-4.DOI: 10.1016/j.vaccine.2015.04.036.
23. Weinstein, N.D., P.M. Sandman, and S.J. Blalock, *The Precaution Adoption Process Model*, in *Health Behavior and Health Education*, K. Glanz, B.K. Rimer, and K. Viswanath, Editors. 2008, Jossey-Bass: San Francisco. p. 123-147.
24. Weinstein, N.D. and P.M. Sandman, *A model of the precaution adoption process: Evidence from home radon testing*. Health Psychol, 1992. **11**(3): p. 170-80.DOI: 10.1037//0278-6133.11.3.170.
25. Reiter, P.L., M.L. Pennell, and M.L. Katz, *Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?* Vaccine, 2020. **38**(42): p. 6500-6507.DOI: 10.1016/j.vaccine.2020.08.043.

26. Waller, J., et al., *Decision-making about HPV vaccination in parents of boys and girls: A population-based survey in England and Wales*. *Vaccine*, 2020. **38**(5): p. 1040-1047.DOI: 10.1016/j.vaccine.2019.11.046.
27. Shapiro, G.K., et al., *Using an integrated conceptual framework to investigate parents' HPV vaccine decision for their daughters and sons*. *Prev Med.* , 2018. **116**: p. 203-210.DOI: 10.1016/j.ypmed.2018.09.017.
28. Greco, C.M., et al., *Measuring nonspecific factors in treatment: Item banks that assess the healthcare experience and attitudes from the patient's perspective*. *Qual Life Res*, 2016. **25**(7): p. 1625-34.DOI: 10.1007/s11136-015-1178-1.
29. Antonopoulou, V., et al., *Policy Brief: Which factors may help increase COVID-19 vaccine uptake in England? Content analysis of free text responses to a survey delivered in Oct/Nov 2020*. 2021, NIHR Policy Research Unit in Behavioural Science.
30. Meyer, P., *Defining and measuring credibility of newspapers: Developing an index*. *Journalism Quarterly*, 1988. **65**(3): p. 567-574.
31. Hamilton, R.A., E.M. Krockow, and P. Vekria, *Attitudes towards influenza and uptake of the flu vaccine: A survey of pharmacy staff working in English hospitals*. *Vaccine*, 2021. **39**(19): p. 2636-2642.DOI: 10.1016/j.vaccine.2021.03.091.
32. Ziarnowski, K.L., N.T. Brewer, and B. Weber, *Present choices, future outcomes: Anticipated regret and HPV vaccination*. *Prev Med.* , 2009. **48**(5): p. 411-414.DOI: <https://doi.org/10.1016/j.ypmed.2008.10.006>.
33. Niesen, M.J.M., et al., *Surveillance of safety of 3 doses of COVID-19 mRNA vaccination using electronic health records*. *JAMA Netw Open*, 2022. **5**(4): p. e227038.DOI: <https://doi.org/10.1001/jamanetworkopen.2022.7038>.
34. Wu, Q., et al., *Evaluation of the safety profile of COVID-19 vaccines: A rapid review*. *BMC Med.*, 2021. **19**(1): p. 173.DOI: 10.1186/s12916-021-02059-5.
35. Menni, C., et al., *Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study*. *The Lancet Infectious Diseases*, 2021. **21**(7): p. 939-949.DOI: 10.1016/S1473-3099(21)00224-3.
36. Andrews, N., et al., *Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: Test negative case-control study*. medRxiv, 2021: p. 2021.11.15.21266341.DOI: 10.1101/2021.11.15.21266341.
37. Garcia-Beltran, W.F., et al., *mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant*. *Cell*, 2022. **185**(3): p. 457–466.e4.DOI: <https://doi.org/10.1016/j.cell.2021.12.033>.
38. Luz, P.M., R.E. Johnson, and H.E. Brown, *Workplace availability, risk group and perceived barriers predictive of 2016–17 influenza vaccine uptake in the United States: A cross-sectional study*. *Vaccine*, 2017. **35**(43): p. 5890-5896.DOI: 10.1016/j.vaccine.2017.08.078.

39. Wheelock, A., et al., *Socio-psychological factors driving adult vaccination: A qualitative study*. PLoS ONE, 2014. **9**(12): p. e113503.DOI: 10.1371/journal.pone.0113503.
40. Teo, L.M., et al., *Attitudes and perception of influenza vaccines among older people in Singapore: A qualitative study*. Vaccine, 2019. **37**(44): p. 6665-6672.DOI: <https://doi.org/10.1016/j.vaccine.2019.09.037>.
41. Marcec, R. and R. Likic, *Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines*. Postgrad. Med. J., 2021.DOI: 10.1136/postgradmedj-2021-140685.
42. Perry, M., et al., *Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK*. Vaccine, 2021. **39**(42): p. 6256-6261.DOI: 10.1016/j.vaccine.2021.09.019.
43. Stead, M., et al., *National survey of attitudes towards and intentions to vaccinate against COVID-19: Implications for communications*. BMJ Open, 2021. **11**(10).DOI: 10.1136/bmjopen-2021-055085.
44. HM Government. *Final report on progress to address COVID-19 health inequalities*. 2021 December 2021 Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1038338/2021-12-03\\_Final\\_COVID-19\\_disparities\\_report\\_updated\\_3\\_Dec.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1038338/2021-12-03_Final_COVID-19_disparities_report_updated_3_Dec.pdf).
45. OpenSAFELY. *OpenSAFELY COVID Vaccine coverage report: Booster / third doses*. 2021 Available from: <https://reports.opensafely.org/reports/vaccine-coverage-thirdbooster-doses/>.
46. Office for National Statistics. *Coronavirus (COVID-19) latest insights: Vaccines*. 2022 Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/vaccines>.
47. UK Health Security Agency. *Guidance: COVID-19 vaccination: guide for employers*. 2021 Available from: <https://www.gov.uk/government/publications/covid-19-vaccination-guide-for-employers/covid-19-vaccination-guide-for-employers>.
48. Acas, *New study reveals 1 in 4 employers are not giving staff paid time off to get COVID vaccinations*. 2021.
49. Vet, R., J.B.F. de Wit, and E. Das, *The efficacy of social role models to increase motivation to obtain vaccination against Hepatitis B among men who have sex with men*. Health Educ. Res., 2010. **26**(2): p. 192-200.DOI: 10.1093/her/cyq074.
50. Scientific Advisory Group for Emergencies. *Factors influencing COVID-19 vaccine uptake among minority ethnic groups, 17 December 2020*. 2021 Available from: <https://www.gov.uk/government/publications/factors-influencing-covid-19-vaccine-uptake-among-minority-ethnic-groups-17-december-2020>.



51. Kamal, A., A. Hodson, and J.M. Pearce, *A rapid systematic review of factors influencing COVID-19 vaccination uptake in minority ethnic groups in the UK*. *Vaccines*, 2021. **9**(10).DOI: 10.3390/vaccines9101121.
52. Khan, M.S., et al., *Rethinking vaccine hesitancy among minority groups*. *Lancet*, 2021. **397**(10288): p. 1863-1865.DOI: 10.1016/S0140-6736(21)00938-7.
53. Michie, S., M.M. van Stralen, and R. West, *The behaviour change wheel: A new method for characterising and designing behaviour change interventions*. *Implement. Sci.*, 2011. **6**(1).DOI: 10.1186/1748-5908-6-42.

Table 1. Sample characteristics (N = 2,004)

Variable		
Age – M (SD)	63.61	(8.45)
Gender – N (%)		
- Female	1,022	(51.00)
- Male	981	(48.95)
- Other	1	(0.05)
Region – N (%)		
- East Midlands	181	(9.03)
- East of England	220	(10.98)
- London	297	(14.82)
- North East	104	(5.19)
- North West	259	(12.92)
- South East	320	(15.97)
- South West	200	(9.98)
- West Midlands	223	(11.13)
- Yorkshire and the Humber	200	(9.98)
Ethnicity – N (%)		
- White British	1,843	(91.97)
- Not white British	155	(7.73)
Education status – N (%)		
- No formal qualification	148	(7.39)
- High school qualification (e.g., BTEC, GCSE, A-levels)	883	(44.06)
- University diploma/degree	512	(25.55)
- Other qualification	453	(22.60)
Employment status – N (%)		
- Employed	751	(37.48)
- Not employed	1,245	(62.13)
Household income – N (%)		
- Less than £30,000	988	(49.30)
- More than £30,000	852	(42.51)
- Prefer not to say	164	(8.18)
Asked to shield – N (%)		
- Yes	397	(19.81)
- No	1,599	(79.79)
Previous COVID-19 infection – N (%)		
- Yes	216	(10.78)
- No	1,786	(89.12)

Table 2. Socio-demographic, socio-economic, and health information for participants, by PAMP stage of decision-making.

	Unengaged (N = 135)	Undecided (N = 262)	Decided NOT to have booster (N = 31)	Decided to have booster (N = 1,415)	Had booster (N = 161)	*Univariate analyses	
						N	pseudo $r^2$
Age – M (SD)	59.21 (6.93)	60.33 (7.71)	62.03 (9.96)	63.87 (7.90)	70.58 (10.09)	1,812	0.033***
Gender – N (%)						1,812	0.002*
- Female or Other	70 (6.84)	152 (14.86)	17 (1.66)	711 (69.50)	73 (7.14)		
- Male	65 (6.63)	110 (11.21)	14 (1.43)	704 (71.76)	88 (8.97)		
Region – N (%)						1,812	0.013**
- East of England	12 (5.45)	35 (15.91)	5 (2.27)	158 (71.82)	10 (4.55)		
- East Midlands	11 (6.08)	13 (7.18)	2 (1.10)	145 (80.11)	10 (5.52)		
- London	28 (9.43)	42 (14.14)	7 (2.36)	183 (61.62)	37 (12.46)		
- North East	10 (9.62)	13 (12.50)	1 (0.96)	71 (68.27)	9 (8.65)		
- North West	14 (5.41)	28 (10.81)	4 (1.54)	190 (73.36)	23 (8.88)		
- South East	21 (6.56)	49 (15.31)	2 (0.63)	221 (69.06)	27 (8.44)		
- South West	6 (3.00)	21 (10.50)	1 (0.50)	158 (79.00)	14 (7.00)		
- West Midlands	20 (8.97)	33 (14.80)	2 (0.90)	151 (67.71)	17 (7.62)		
- Yorkshire & the Humber	13 (6.50)	28 (14.00)	7 (3.50)	138 (69.00)	14 (7.00)		
Ethnicity – N (%)						1,807	0.009***
- White British	115 (6.24)	225 (12.21)	25 (1.36)	1,328 (72.06)	150 (8.14)		
- Not white British	19 (12.26)	35 (22.58)	6 (3.87)	85 (54.84)	10 (6.45)		
Education status – N (%)						1,806	0.007**
- No formal qualification	19 (12.84)	16 (10.81)	3 (2.03)	95 (64.19)	15 (10.14)		
- High school qualification	58 (6.57)	136 (15.40)	14 (1.59)	618 (69.99)	57 (6.46)		
- University diploma/degree	34 (6.64)	54 (10.55)	8 (1.56)	375 (73.24)	41 (8.01)		
- Other qualification	24 (5.30)	53 (11.70)	5 (1.10)	324 (71.52)	47 (10.38)		
Employment status – N (%)						1,806	0.013***
- Employed	75 (9.99)	120 (15.98)	11 (1.46)	496 (66.05)	49 (6.52)		
- Not employed	58 (4.66)	141 (11.33)	19 (1.53)	916 (73.57)	111 (8.92)		
Key worker status – N (%)						1,812	0.008***
- Yes	32 (10.36)	56 (18.12)	4 (1.29)	186 (60.19)	31 (10.03)		
- No	103 (6.08)	206 (12.15)	27 (1.59)	1,229 (72.51)	130 (7.67)		

	<b>Unengaged</b>	<b>Undecided</b>	<b>Decided NOT to have booster</b>	<b>Decided to have booster</b>	<b>Had booster</b>	<b>†Univariate analyses</b>	
	(N = 135)	(N = 262)	(N = 31)	(N = 1,415)	(N = 161)	<b>N</b>	<b>pseudo r<sup>2</sup></b>
Health or social care worker – N (%)						1,812	0.001
- Yes	5 (5.62)	14 (15.73)	2 (2.25)	42 (47.19)	26 (29.21)		
- No	130 (6.79)	248 (12.95)	29 (1.51)	1,373 (71.70)	135 (7.05)		
Household income – N (%)						1,812	0.004**
- Less than £30,000	47 (5.52)	101 (11.85)	6 (0.70)	624 (73.24)	74 (8.69)		
- More than £30,000	78 (7.89)	144 (14.57)	18 (1.82)	670 (67.81)	78 (7.89)		
- Prefer not to say	10 (6.10)	17 (10.37)	7 (4.27)	121 (73.78)	9 (5.49)		
General health – M (SD)	2.39 (0.86)	2.38 (0.95)	2.77 (0.96)	2.44 (0.83)	2.56 (0.96)	1,808	0.001
Asked to shield – N (%)						1,806	0.002*
- Yes	19 (4.79)	40 (10.08)	4 (1.01)	278 (70.03)	56 (14.11)		
- No	115 (7.19)	221 (13.82)	26 (1.63)	1,133 (70.86)	104 (6.50)		
Previous COVID-19 infection – N (%)						1,811	0.003**
- Yes	17 (7.87)	40 (18.52)	8 (3.70)	137 (63.43)	14 (6.48)		
- No	118 (6.61)	222 (12.43)	23 (1.29)	1,277 (71.50)	146 (8.17)		

*Note.* PAPM = precaution adoption process model. † based on univariate multinomial regression model, with reference category 'Stage 5: Decided to have booster'; stages 4 (decided NOT to have booster) and 6 (had booster) were excluded from regression analyses. \*  $p < 0.10$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$ .

Table 3. Experiences, attitudes, and beliefs about COVID-19 (booster) vaccination, by PAPM stage of decision-making.

	Unengaged (N = 135)	Undecided (N = 262)	Decided NOT to have booster (N = 31)	Decided to have booster (N = 1,415)	Had booster (N = 161)	†Univariate analyses	
						N	pseudo $r^2$
<b>Previous COVID-19 vaccine experience</b>							
Previous vaccine – N (%)						1,791	0.008***
- Pfizer/BioNTech	23 (3.99)	45 (7.80)	7 (1.21)	393 (68.11)	109 (18.89)		
- Oxford/AstraZeneca	107 (7.62)	215 (15.31)	23 (1.64)	1,008 (71.79)	51 (3.63)		
Overall experience – M (SD)	4.18 (0.75)	4.21 (0.65)	3.35 (0.95)	4.60 (0.49)	4.72 (0.47)	1,811	0.056***
Healthcare environment – M (SD)	4.65 (0.54)	4.59 (0.56)	4.42 (0.87)	4.77 (0.43)	4.84 (0.36)	1,812	0.013***
Patient-provider connection – M (SD)	4.56 (0.64)	4.47 (0.70)	4.14 (1.04)	4.75 (0.53)	4.85 (0.38)	1,812	0.023***
Access – M (SD)	4.46 (0.74)	4.43 (0.72)	4.60 (0.55)	4.63 (0.59)	4.77 (0.45)	1,812	0.011***
Perceived benefits – M (SD)	4.09 (0.75)	4.04 (0.64)	3.45 (0.97)	4.45 (0.57)	4.59 (0.53)	1,694	0.049***
<b>Psychological constructs</b>							
Perceived severity – M (SD)	3.05 (1.05)	3.17 (1.02)	3.16 (0.97)	3.38 (1.02)	3.50 (1.06)	1,812	0.008***
Perceived susceptibility – M (SD)							
- likelihood coming into contact with person with COVID-19	3.14 (0.92)	3.30 (1.01)	2.94 (1.12)	3.44 (0.93)	3.52 (0.96)	1,812	0.007***
- good immunity to COVID-19	3.66 (0.79)	3.55 (0.81)	3.52 (1.03)	3.85 (0.80)	4.12 (0.84)	1,812	0.015***
- immune system strong enough	3.49 (0.87)	3.30 (0.97)	3.68 (0.79)	3.17 (1.05)	3.57 (1.16)	1,812	0.006***
Perceived benefits – M (SD)	3.76 (0.74)	3.77 (0.61)	2.62 (0.93)	4.26 (0.56)	4.26 (0.57)	1,812	0.084***
Perceived safety – M (SD)	3.60 (0.87)	3.44 (0.84)	2.21 (1.10)	4.20 (0.69)	4.46 (0.61)	1,812	0.104***
Booster vaccine attitudes – M (SD)	3.92 (0.71)	3.86 (0.62)	2.58 (0.95)	4.58 (0.50)	4.74 (0.42)	1,812	0.167***
Subjective norms – M (SD)	3.58 (0.78)	3.64 (0.65)	2.94 (0.81)	4.21 (0.63)	4.46 (0.62)	1,812	0.098***
Perceived control – M (SD)	3.91 (0.95)	3.83 (0.89)	3.94 (1.03)	4.49 (0.70)	4.71 (0.53)	1,812	0.076***
Anticipated regret – M (SD)	4.02 (1.34)	4.15 (1.22)	2.72 (1.23)	4.69 (0.92)	4.62 (1.05)	1,812	0.035***
Booster vaccine knowledge – M (SD)	3.32 (1.02)	3.38 (0.90)	2.92 (0.99)	4.21 (0.70)	4.53 (0.53)	1,812	0.132***
Trust – M (SD)	3.53 (0.90)	3.47 (0.86)	2.10 (1.22)	4.09 (0.84)	4.29 (0.80)	1,812	0.057***
Fear of needles – N (%)						1,781	0.004***
- Yes	28 (9.18)	53 (17.38)	8 (2.62)	196 (64.26)	20 (6.56)		
- No	102 (6.13)	203 (12.19)	21 (1.26)	1,199 (72.01)	140 (8.41)		

Note. PAPM = precaution adoption process model. † based on univariate multinomial regression model, with reference category 'Stage 5: Decided to have booster'; stages 4 (decided NOT to have booster) and 6 (had booster) were excluded from regression analyses. \*  $p < 0.10$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$ .

*Table 4.* Multivariate, multinomial backward stepwise logistic regression model for different stages of decision making about getting the COVID-19 booster vaccine, represented by PAPM stage, displaying adjusted relative risk ratios and 95% CIs (N = 1,637)

	<b>Decided to have the booster vaccine (n = 1,300) vs.</b>	
	<b>Unengaged (n = 106)</b>	<b>Undecided (n = 231)</b>
First vaccine Oxford/AstraZeneca (vs Pfizer/BioNTech)	1.461 [0.840,2.542]	1.638* [1.085,2.472]
Previous COVID-19 vaccine: Overall experience	0.574** [0.391,0.843]	0.692* [0.516,0.928]
Booster vaccine knowledge	0.384*** [0.275,0.537]	0.510*** [0.391,0.665]
Booster vaccine attitudes	0.689 [0.415,1.144]	0.284*** [0.193,0.418]
Subjective norms	0.556** [0.373,0.829]	0.750 [0.550,1.022]
Anticipated regret	0.799* [0.662,0.966]	0.843* [0.727,0.977]
Perceived susceptibility: believe my immune system is strong enough to protect me against COVID-19	1.927*** [1.472,2.522]	1.383*** [1.142,1.676]
White British (vs not White British)	0.533 [0.262,1.082]	0.518* [0.292,0.920]
Currently employed (vs not employed)	2.508*** [1.565,4.020]	1.295 [0.912,1.837]
Household income less than £30,000 (vs more than £30,000)	1.644* [1.037,2.605]	1.380 [0.979,1.944]
Education		
- No qualification	(reference)	(reference)
- High school qualification	0.363** [0.177,0.743]	1.470 [0.741,2.915]
- University diploma/degree	0.406* [0.182,0.906]	1.138 [0.537,2.414]
- Other qualification	0.365* [0.162,0.824]	1.337 [0.639,2.797]
Live in East Midlands (vs London)	0.453 [0.194,1.060]	0.362** [0.183,0.715]

*Note.* PAPM = precaution adoption process model. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . pseudo  $R^2 = 0.249$ .

## Appendix A. Overview of subscale items included in the analysis

Subscale and included items	Scale / response options	Cronbach's alpha
<b>PAPM STAGE</b>		n/a
<ul style="list-style-type: none"> <li>Which of the following best describes your thoughts about having a COVID-19 booster vaccine, once Public Health authorities recommend you have one?</li> </ul>	"I've not yet thought about having a booster vaccine" (Stage 2); "I'm not yet sure about having a booster vaccine, but will probably (not) have it" (Stage 3); "I've decided I don't want to have a booster vaccine" (Stage 4); "I've decided I do want to have a booster vaccine" (Stage 5); and "I have had the booster vaccine" (Stage 6)	
<b>PREVIOUS COVID-19 VACCINE EXPERIENCE</b>		
<b>Previous COVID-19 vaccine: Overall experience</b> <ul style="list-style-type: none"> <li>Having the vaccine was ... <i>painful / tolerable</i></li> <li>I believe the vaccine was ... <i>worthless / valuable</i></li> <li>After having the first COVID-19 vaccine, I experienced ... <i>strong side effects / no side effects</i></li> <li>After having the second COVID-19 vaccine, I experienced ... <i>strong side effects / no side effects</i></li> <li>Overall, I found having the vaccine was ... <i>a terrible experience / a good experience</i></li> </ul>	5-point scale	0.70
<b>Previous COVID-19 vaccine: Healthcare environment</b> <ul style="list-style-type: none"> <li>The staff were respectful</li> <li>The staff were friendly</li> <li>The staff were helpful</li> <li>My care was well organized</li> <li>My privacy was respected</li> <li>The waiting area was comfortable</li> </ul>	5-point scale ( <i>not at all – very much</i> )	0.87
<b>Previous COVID-19 vaccine: Patient-provider connection</b> <ul style="list-style-type: none"> <li>I trusted them</li> <li>They paid attention to my individual needs</li> <li>They gave me enough information</li> <li>They gave me support and encouragement</li> </ul>	5-point scale ( <i>not at all – very much</i> )	0.91
<b>Previous COVID-19 vaccine: Access</b> <ul style="list-style-type: none"> <li>Booking my second COVID-19 vaccine was easy</li> <li>Getting to the place where I had my second COVID-19 vaccine was easy</li> <li>I was happy with the venue where I received my second dose</li> </ul>	5-point scale ( <i>strongly disagree – strongly agree</i> )	0.79

Subscale and included items	Scale / response options	Cronbach's alpha
<b>Previous COVID-19 vaccine: Perceived benefits</b> <ul style="list-style-type: none"> <li>• My health is better protected now that I have been vaccinated</li> <li>• I have done all I can to protect my family and friends now that I have been vaccinated</li> <li>• I am less nervous, anxious, or on edge now that I have been vaccinated</li> </ul>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	0.68
<b>PSYCHOLOGICAL CONSTRUCTS</b>		
<b>HEALTH BELIEF MODEL</b>		
<b>Perceived severity</b> <ul style="list-style-type: none"> <li>• Despite already being fully vaccinated (have received at least two doses), I believe I would be very sick if I got COVID-19</li> </ul>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	n/a
<b>Perceived susceptibility</b> <ul style="list-style-type: none"> <li>• There is a high chance I will come into contact with a person with COVID-19 over the next few weeks</li> <li>• I believe I will still have good immunity to COVID-19, six months after having the vaccine</li> <li>• I believe my immune system is strong enough to protect me against COVID-19</li> </ul>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	*0.33
<b>Perceived benefits</b> <ul style="list-style-type: none"> <li>• A COVID-19 booster vaccine will protect me against catching COVID-19</li> <li>• A COVID-19 booster vaccine would reduce the severity of a possible future COVID-19 infection</li> <li>• If I have a COVID-19 booster vaccine, I would be less likely to spread COVID-19 to others</li> <li>• A mass COVID-19 booster vaccine programme will protect the vulnerable from catching COVID-19</li> <li>• A mass COVID-19 booster vaccine programme, will help protect the NHS</li> <li>• A mass COVID-19 booster vaccine programme could prevent the re-introduction of protection measures such as social distancing</li> </ul>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	0.87
<b>Perceived safety</b> <ul style="list-style-type: none"> <li>• I believe that an approved COVID-19 booster vaccine will be very safe</li> <li>• I'm NOT concerned about the possible side effects of a COVID-19 booster vaccine</li> </ul>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	0.70
<b>THEORY OF PLANNED BEHAVIOUR</b>		
<b>Vaccine attitudes</b> <ul style="list-style-type: none"> <li>• Having a COVID-19 booster vaccine would be beneficial</li> <li>• Having a COVID-19 booster vaccine would be tolerable</li> </ul>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	0.78
<b>Subjective norms</b>	5-point scale ( <i>strongly disagree</i> – <i>strongly agree</i> )	0.75 (3)



Subscale and included items	Scale / response options	Cronbach's alpha
<ul style="list-style-type: none"> <li>• My family would expect me to have a COVID-19 booster vaccine</li> <li>• My GP would expect me to have a COVID-19 booster vaccine</li> <li>• †My employer would expect me to have a COVID-19 booster vaccine</li> <li>• My family and friends have said they would get the COVID-19 booster vaccine once it's available to them</li> </ul>	– <i>strongly agree</i> )	items) / 0.79 (4 items)
<b>Perceived control</b>	5-point scale ( <i>strongly disagree</i>	n/a
<ul style="list-style-type: none"> <li>• I feel in total control as to whether I will have a COVID-19 booster vaccine</li> </ul>	– <i>strongly agree</i> )	
<b>Anticipated regret</b>	5-point scale ( <i>not at all – a</i>	0.97
How much would you regret that you did not get a COVID-19 booster vaccine if it was recommended you have one?	<i>great deal</i> )	
<ul style="list-style-type: none"> <li>• You were hospitalised and admitted to the intensive care unit as a result of a COVID-19 infection</li> <li>• You caught COVID-19 and passed it on to a friend</li> <li>• You caught COVID-19 and passed it on to a family member</li> </ul>		
<b>OTHER FACTORS</b>		
<b>Vaccine knowledge</b>	5-point scale ( <i>strongly disagree</i>	0.89
<ul style="list-style-type: none"> <li>• I know enough about the safety of a COVID-19 booster vaccine, to make an informed decision about whether or not to get the vaccine booster</li> <li>• I know enough about how the COVID-19 booster vaccine will help reduce the spread of the virus</li> <li>• I know enough about how effective the COVID-19 booster vaccine will be, to make an informed decision about whether or not to get the vaccine booster</li> </ul>	– <i>strongly agree</i> )	
<b>Trust</b>	5-point scale ( <i>strongly disagree</i>	n/a
<ul style="list-style-type: none"> <li>• Information from the Government about the COVID-19 booster vaccine can be trusted</li> </ul>	– <i>strongly agree</i> )	
<b>Fear of needles</b>	Yes / no / don't know	n/a
<ul style="list-style-type: none"> <li>• I am scared of needles</li> </ul>		

Note. †each item represented separately in analyses due to low internal consistency; ‡only asked to people who reported they were employed

**Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Falko F Sniehotta reports financial support was provided by National Institute of Health and Medical Research.

## Highlights

- About 20% of people >50 years sampled in England (N = 2,004) had not yet decided to have the COVID-19 booster vaccine.
- Stage theory captures qualitative differences in those who have not had the COVID-19 booster vaccine.
- Improving knowledge of vaccine safety and effectiveness is a priority in the vaccine hesitant.
- Less financial security and less social pressure is associated with being unengaged in decision to have the booster vaccine.
- More negative attitudes towards booster vaccination, vaccine type, and not being of white British ethnicity is associated with being undecided about booster vaccination.